|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
183,678,000 |
Market
Cap: |
4.26(B) |
Last
Volume: |
775,760 |
Avg
Vol: |
773,642 |
52
Week Range: |
$23.21 - $33.63 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 581 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
35,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
10,417 |
15,666 |
48,238 |
96,962 |
Total Sell Value |
$292,740 |
$454,291 |
$1,411,373 |
$2,911,362 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
3 |
6 |
8 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cooke Shane |
President, Alkermes plc |
|
2018-02-02 |
4 |
AS |
$60.38 |
$4,407,679 |
D/D |
(72,793) |
74,708 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-02-02 |
4 |
OE |
$16.55 |
$1,204,724 |
D/D |
72,793 |
147,501 |
|
- |
|
Mitchell Paul J |
Director |
|
2018-02-01 |
4 |
AS |
$56.77 |
$56,770 |
D/D |
(1,000) |
8,000 |
|
- |
|
Mitchell Paul J |
Director |
|
2018-02-01 |
4 |
OE |
$11.44 |
$11,440 |
D/D |
1,000 |
9,000 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-01-29 |
4 |
AS |
$60.00 |
$198,000 |
D/D |
(3,300) |
74,708 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-01-29 |
4 |
OE |
$16.55 |
$54,615 |
D/D |
3,300 |
78,008 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-01-26 |
4 |
AS |
$60.02 |
$102,028 |
D/D |
(1,700) |
74,708 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-01-26 |
4 |
OE |
$16.55 |
$28,135 |
D/D |
1,700 |
76,408 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-01-11 |
4 |
AS |
$60.22 |
$373,809 |
D/D |
(6,207) |
74,708 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2018-01-11 |
4 |
OE |
$16.55 |
$102,726 |
D/D |
6,207 |
80,915 |
|
- |
|
Mitchell Paul J |
Director |
|
2018-01-02 |
4 |
AS |
$54.99 |
$54,990 |
D/D |
(1,000) |
8,000 |
|
- |
|
Mitchell Paul J |
Director |
|
2018-01-02 |
4 |
OE |
$11.44 |
$11,440 |
D/D |
1,000 |
9,000 |
|
- |
|
Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
|
2017-12-29 |
4 |
AS |
$54.81 |
$583,886 |
D/D |
(10,652) |
16,943 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
38,256 |
|
- |
|
Anstice David W |
Director |
|
2017-12-13 |
4 |
OE |
$11.44 |
$457,600 |
D/D |
40,000 |
55,000 |
|
- |
|
Mitchell Paul J |
Director |
|
2017-12-01 |
4 |
AS |
$51.98 |
$51,980 |
D/D |
(1,000) |
8,000 |
|
- |
|
Mitchell Paul J |
Director |
|
2017-12-01 |
4 |
OE |
$11.44 |
$11,440 |
D/D |
1,000 |
9,000 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-11-29 |
4 |
AS |
$50.49 |
$1,057,249 |
D/D |
(20,932) |
144,039 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-11-29 |
4 |
OE |
$12.29 |
$257,254 |
D/D |
20,932 |
164,971 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-11-08 |
4 |
AS |
$47.58 |
$996,009 |
D/D |
(20,932) |
144,039 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-11-08 |
4 |
OE |
$12.29 |
$257,254 |
D/D |
20,932 |
164,971 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-11-02 |
4 |
AS |
$48.87 |
$2,443,410 |
D/D |
(50,000) |
637,686 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-11-02 |
4 |
OE |
$14.13 |
$706,500 |
D/D |
50,000 |
687,686 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-11-01 |
4 |
AS |
$48.71 |
$730,688 |
D/D |
(15,000) |
163,693 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-11-01 |
4 |
OE |
$14.13 |
$211,950 |
D/D |
15,000 |
178,693 |
|
- |
|
2018 Records found
|
|
Page 28 of 81 |
|
|